AI Article Synopsis
- - Alzheimer’s disease (AD) is the leading cause of dementia and poses significant global healthcare challenges, primarily due to its complex nature that makes drug development difficult.
- - Recent approvals of drugs like aducanumab, lecanemab, and sodium oligomannate mark a significant breakthrough in AD treatment after a long period without new options, transforming the therapeutic landscape for the disease.
- - Natural products are showing potential in AD research and are being investigated in clinical trials, offering promising new treatment possibilities to work alongside existing therapies.
Article Abstract
Alzheimer's disease (AD) remains the foremost cause of dementia and represents a significant unmet healthcare need globally. The complex pathogenesis of AD, characterized by various pathological and physiological events, has historically challenged the development of anti-AD drugs. However, recent breakthroughs in AD drug development, including the approvals of aducanumab, lecanemab, and sodium oligomannate (GV-971), have ended a nearly two-decade hiatus in the introduction of new AD drugs. These developments have addressed long-standing challenges in AD drug development, marking a substantial shift in the therapeutic landscape of AD. Moreover, natural products (NPs) have shown promise in AD drug research, with several currently under clinical investigation. Their distinct properties and mechanisms of action offer new avenues to complement and enhance existing AD treatment approaches. This review article aims to provide an overview of the recent advancements and prospects in AD therapeutics, focusing on both NPs and approved drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1875-5364(24)60606-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!